BHC
Price
$7.29
Change
-$0.07 (-0.95%)
Updated
Sep 8, 12:39 PM (EDT)
Capitalization
2.72B
52 days until earnings call
VTRS
Price
$10.41
Change
-$0.09 (-0.86%)
Updated
Sep 8, 01:38 PM (EDT)
Capitalization
12.24B
63 days until earnings call
Interact to see
Advertisement

BHC vs VTRS

Header iconBHC vs VTRS Comparison
Open Charts BHC vs VTRSBanner chart's image
Bausch Health Companies
Price$7.29
Change-$0.07 (-0.95%)
Volume$100
Capitalization2.72B
Viatris
Price$10.41
Change-$0.09 (-0.86%)
Volume$1.78K
Capitalization12.24B
BHC vs VTRS Comparison Chart in %
Loading...
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHC vs. VTRS commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (BHC: $7.35 vs. VTRS: $10.50)
Brand notoriety: BHC: Notable vs. VTRS: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 36% vs. VTRS: 88%
Market capitalization -- BHC: $2.72B vs. VTRS: $12.24B
BHC [@Pharmaceuticals: Generic] is valued at $2.72B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.24B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • BHC’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, both BHC and VTRS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • BHC’s TA Score: 5 bullish, 6 bearish.
  • VTRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than BHC.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а -0.94% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -0.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

BHC is expected to report earnings on Oct 30, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.2B) has a higher market cap than BHC($2.73B). VTRS has higher P/E ratio than BHC: VTRS (236.20) vs BHC (28.27). BHC YTD gains are higher at: -8.809 vs. VTRS (-12.394). BHC has more cash in the bank: 1.73B vs. VTRS (406M). VTRS has less debt than BHC: VTRS (14.5B) vs BHC (21.7B).
BHCVTRSBHC / VTRS
Capitalization2.73B12.2B22%
EBITDA3BN/A-
Gain YTD-8.809-12.39471%
P/E Ratio28.27236.2012%
Revenue9.86BN/A-
Total Cash1.73B406M425%
Total Debt21.7B14.5B150%
FUNDAMENTALS RATINGS
BHC vs VTRS: Fundamental Ratings
BHC
VTRS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3944
P/E GROWTH RATING
1..100
261
SEASONALITY SCORE
1..100
3550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is in the same range as BHC (35) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

BHC's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as VTRS (44) in the null industry. This means that BHC’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as BHC (26) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCVTRS
RSI
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
66%
Momentum
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
57%
MACD
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 4 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
62%
Advances
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
68%
Declines
ODDS (%)
Bearish Trend 5 days ago
78%
Bearish Trend 5 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
59%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MMIN23.300.15
+0.65%
NYLI MacKay Muni Insured ETF
VABS24.620.02
+0.08%
Virtus Newfleet ABS/MBS ETF
JHDV38.71N/A
N/A
JHancock U.S. High Dividend ETF
GAB6.14-0.02
-0.32%
Gabelli Equity Trust (The)
ETHD3.56-0.09
-2.47%
Proshares UltraShort Ether ETF

BHC and

Correlation & Price change

A.I.dvisor tells us that BHC and AMPH have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BHC and AMPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
+1.94%
AMPH - BHC
27%
Poorly correlated
+0.79%
PAHC - BHC
26%
Poorly correlated
+0.97%
SWDCF - BHC
25%
Poorly correlated
N/A
VTRS - BHC
25%
Poorly correlated
+1.65%
PRGO - BHC
23%
Poorly correlated
-2.75%
More